You are here

Takeda

Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says

Fierce Pharma

Wed, 08/25/21 - 09:32 pm

hereditary angiodema

Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases

BioSpace

Mon, 08/23/21 - 11:13 am

Genevant Sciences

drug development

Takeda Settles "Pay-for-Delay" Consumer Claims for $1.85 Million

BioSpace

Thu, 08/12/21 - 12:07 am

Takeda still on the hook for €398M tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

Mon, 08/2/21 - 09:40 pm

Takeda allies with Frazier to spin out late-phase norovirus vaccine

Fierce Biotech

Fri, 07/30/21 - 11:09 am

Frazier Healthcare

Takeda fleshes out CNS pact with peptide drugmaker, setting aside $3.5B in future milestones

Endpoints

Tue, 07/27/21 - 10:31 am

Takeda lays out $126M to tap robotics, virtual reality and more at California production site

Fierce Pharma

Sun, 07/25/21 - 11:47 am

The top 15 blockbuster patent expirations coming this decade

Fierce Pharma

Mon, 07/12/21 - 11:08 am

Boehringer, Lilly and Takeda join matchmaker PharmStars' digital health accelerator

Fierce Pharma

Wed, 06/16/21 - 11:50 am

Boehringer Ingelheim

Five Collaborations Unlocking Faster Drug Development this Week

BioSpace

Thu, 06/10/21 - 11:12 am

drug development

pulmonary fibrosis

Oyster Point Pharma

Adaptive Phage Therapeutics

clinical trials

Shoreline Biosciences

After Sanofi’s setbacks, Takeda eyes finish line with its dengue vaccine

Pharmaforum

Mon, 05/24/21 - 10:55 am

clinical trials

FDA Accepts NDA for Takeda’s Maribavir

BioSpace

Sun, 05/23/21 - 02:56 pm

post-transplant cytomegalovirus

Takeda tees up priority review for storied CMV drug from its $62B Shire buyout

Endpoints

Fri, 05/21/21 - 10:51 am

Takeda fleshes out case for oral EGFR drug with follow-up pivotal data in non-small cell lung cancer

Endpoints

Wed, 05/19/21 - 11:14 pm

non-small cell lung cancer

Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict

Fierce Pharma

Wed, 05/19/21 - 11:05 pm

With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO

Fierce Pharma

Tue, 05/11/21 - 11:15 am

The retreat of corporate venture funding?

EP Vantage

Fri, 04/23/21 - 11:02 am

venture funding

venture capital

Boehringer Ingelheim

Bristol Myers Squibb

2,400 people remain without rare disease drug as Takeda manufacturing woes continue

Endpoints

Mon, 04/5/21 - 02:55 pm

hypoparathyroidism

drug manufacturing

Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test

BioPharma Dive

Mon, 04/5/21 - 02:43 pm

Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m

Pharmaceutical Business Review

Thu, 04/1/21 - 10:50 am

Pages